Plus Therapeutics (NASDAQ:PSTV) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

Separately, Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd.

Plus Therapeutics Trading Up 1.6 %

NASDAQ:PSTV opened at $1.28 on Tuesday. Plus Therapeutics has a 12 month low of $1.12 and a 12 month high of $2.67. The firm’s 50 day moving average is $1.35 and its 200 day moving average is $1.61. The stock has a market capitalization of $7.55 million, a PE ratio of -0.51 and a beta of 0.69.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent quarter. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.